Tag: Heart / Stroke-Related: High Cholesterol
Measuring Plasma PCSK9 May ID Resistance to PCSK9 Inhibitors
Most patients experience increase of at least 3.7-fold in plasma PCSK9 levels after treatment
The American Heart Association, Nov. 11-15
The American Heart Association's Scientific Sessions The annual meeting of the American Heart Association was held from Nov. 11 to 15 in...
Rate of Approval for PCSK9i Therapy 47 Percent
Clinical factors and payer type linked to likelihood of approval, with highest approval for Medicare
About Half of Patients Receive Approval for PCSK9i Prescription
Prescription abandonment linked to copay costs, with rates more than 75 percent for copays > $350
Anagliptin Effect on LDL in T2DM Via ApoB-100 Synthesis
Improvement appears mediated, at least in part, through suppression of apoB-100 synthesis
Anacetrapib Linked to Lower Incidence of Coronary Events
Lower incidence versus placebo for patients with atherosclerotic vascular dz receiving intensive statins
More Evidence Evolocumab Exceeds Cost-Effectiveness
Findings for addition of evolocumab to standard tx in atherosclerotic cardiovascular disease
Cost-Effectiveness of PCSK9 Inhibitors Called Into Question
Researchers say price would have to be between $4,000 and $5,000 per year to be cost-effective
Evolocumab Doesn’t Affect Cognition When Added to Statins
No significant between-group difference for patients receiving evolocumab or placebo added to statins
Case Highlights Polygenic Risk in Severe Hypertriglyceridemia
Patient with hypertriglyceridemia had polymorphisms producing triglyceride risk score of 19
